Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis
Open Access
- 21 November 2019
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 59 (3), 297-309
- https://doi.org/10.1007/s40262-019-00840-7
Abstract
The clinical pharmacology of elagolix was extensively evaluated in clinical studies in healthy subjects and in women with endometriosis. Elagolix pharmacokinetics (PK) show significant population variability, however they are minimally affected by patients’ baseline characteristics and demographics, except for clinically relevant extrinsic and intrinsic factors such as coadministrated strong organic anion transporting polypeptide (OATP) 1B1 inhibitors and severe hepatic impairment, which are contraindications for the use of elagolix. These studies enabled a comprehensive understanding of elagolix mechanism of action and the downstream pharmacodynamic (PD) effects on gonadotropin and ovarian hormones, as well as full characterization of the PK/PD (PKPD) relationships of elagolix at various dosages, including the approved 150 mg once daily and 200 mg twice daily dosing regimens for the management of moderate to severe pain associated with endometriosis. Several model-based analyses have contributed to understanding of the benefit–risk profile of elagolix in patients with endometriosis, through characterization of the exposure relationship with responder rates, with changes in bone mineral density over time, as well as the interaction with coadministered drugs. Collectively, these studies and analyses served as supportive evidence for the effectiveness of the approved dosages and provided general dosing instructions of the first approved oral gonadotropin-releasing hormone receptor antagonist.Funding Information
- AbbVie
This publication has 19 references indexed in Scilit:
- Dose-Dependent Suppression of Gonadotropins and Ovarian Hormones by Elagolix in Healthy Premenopausal WomenJournal of Clinical Endocrinology & Metabolism, 2017
- Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy SubjectsClinical Pharmacology in Drug Development, 2016
- Brown adipose tissue and boneInternational Journal of Obesity Supplements, 2015
- The pharmacokinetics of sertraline in overdose and the effect of activated charcoalBritish Journal of Clinical Pharmacology, 2015
- Racial/ethnic differences in bone mineral density among older womenJournal of Bone and Mineral Metabolism, 2012
- Fat and boneArchives of Biochemistry and Biophysics, 2010
- Racial/Ethnic Differences in Bone Mineral Density of Young Adults2010
- Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist ElagolixJournal of Clinical Endocrinology & Metabolism, 2009
- Discovery of Sodium R-(+)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (Elagolix), a Potent and Orally Available Nonpeptide Antagonist of the Human Gonadotropin-Releasing Hormone ReceptorJournal of Medicinal Chemistry, 2008
- The beneficial effects of body fat and adipose tissue in humans*International Journal of Obesity, 1997